Bavarian Nordic drops cancer vaccine efforts to focus on infectious diseases

21 Feb 2024
endpts.com
VaccinePhase 1Immunotherapy
Bavarian Nordic will no longer work on its immuno-oncology vaccine program to instead focus on infectious disease R&D, with the company’s “record” 2023 sales buoyed by its mpox vaccine Jynneos.
The Danish biotech was working on a Phase I cancer vaccine, dubbed TAEK-VAC, which targets a tumor-associated antigen. The asset was being investigated in subjects with chordoma (tumor in the spine or at the base of the skull) or HER2-positive breast cancer.
Bavarian Nordic drops cancer vaccine efforts to focus on infectious diseases
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.